Evidence map›Paper›PMID 42449389›Full record

ArticleJournal of neuroinflammation2026

Ferritin-ApoE nanocarrier for targeted therapy of neuromyelitis optica spectrum disorder in mice.

Xin Zhao, Qian Liang, Kangqi Lin, Shihe Jiang, Tian Yang, Mengjiao Sun, Run Song, Junqiang Yan, Sara Palma-Tortosa, Zaal Kokaia and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xin Zhao *Department of Neurology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, No.636 Guanlin Road, Luolong District, Luoyang, 471003, China.
Qian Liang *Nanozyme Laboratory in Zhongyuan, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, 451163, China.
Kangqi LinChina National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing, 100070, China.
Shihe JiangChina National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing, 100070, China.
Tian YangChina National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing, 100070, China.
Mengjiao SunChina National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing, 100070, China.
Run SongChina National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing, 100070, China.
Junqiang YanDepartment of Neurology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, No.636 Guanlin Road, Luolong District, Luoyang, 471003, China.
Sara Palma-TortosaLaboratory of Stem Cells and Restorative Neurology, Lund Stem Cell Center, Lund University, Lund, 22184, Sweden.
Zaal KokaiaLaboratory of Stem Cells and Restorative Neurology, Lund Stem Cell Center, Lund University, Lund, 22184, Sweden.
Xiyun YanNanozyme Laboratory in Zhongyuan, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, 451163, China.
Ganqin DuDepartment of Neurology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, No.636 Guanlin Road, Luolong District, Luoyang, 471003, China. dgq99@163.com.
Kelong FanNanozyme Laboratory in Zhongyuan, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, 451163, China. fankelong@ibp.ac.cn.
Wei-Na JinDepartment of Neurology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, No.636 Guanlin Road, Luolong District, Luoyang, 471003, China. weina.jin@ncrcnd.org.cn.

Funding

Key Program of Nanozyme Laboratory in Zhongyuan NLZ-KP2024BIC04National Natural Science Foundation of China 32201167National Natural Science Foundation of China 82371324
6 · The paper itself

Abstract

backgroundNeuromyelitis optica spectrum disorder (NMOSD) is a chronic inflammatory autoimmune disease affecting the central nervous system (CNS), characterized by anti-aquaporin 4 (AQP4) antibody-mediated damage to astrocytes, resulting in subsequent demyelination. Our prior work identified the protective effects of the apolipoprotein E

methodsHFn-ApoE

resultsThe HFn-ApoE

conclusionThis study demonstrates that the engineered nanodrug HFn-ApoE

Indexed as

ApoferritinsApolipoproteins EDrug CarriersNanoparticlesNeuromyelitis OpticaAnimalsBlood-Brain BarrierDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred C57BLApoferritinsApolipoproteins EDrug CarriersApolipoprotein E (ApoE)Human heavy-chain ferritin nanocarrier (HFn)Low-density lipoprotein receptor-related protein 1 (LRP1)-NF-κB signalingNeuromyelitis optica spectrum disorder

Identifiers

PMID42449389
PMCPMC13647798

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.